Cargando…

Management of Chemotherapy for Stage II Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy Era: A Review

Nasopharyngeal carcinoma is an endemic disease with a high prevalence in Southeast Asia, Mediterranean countries, and Northern Africa. With substantial advances in screening and diagnosis, increasingly more early-stage (stage I~II) patients are being diagnosed. The undebated treatment modality for s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Peng, Zhao, Yumei, Xiang, Li, Yang, Linglin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7020924/ https://www.ncbi.nlm.nih.gov/pubmed/32104077 http://dx.doi.org/10.2147/CMAR.S239729

Ejemplares similares

The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis
por: Liu, Fang, et al.
Publicado: (2018)

Concurrent Chemotherapy for T4 Classification Nasopharyngeal Carcinoma in the Era of Intensity-Modulated Radiotherapy
por: Cao, Cai-neng, et al.
Publicado: (2015)

Addition of chemotherapy to intensity-modulated radiotherapy does not improve survival in stage II nasopharyngeal carcinoma patients
por: Fangzheng, Wang, et al.
Publicado: (2018)

Recommendations for Updating T and N Staging Systems for Nasopharyngeal Carcinoma in the Era of Intensity-Modulated Radiotherapy
por: Liang, Zhong-Guo, et al.
Publicado: (2016)

T4/N2 classification nasopharyngeal carcinoma benefit from concurrent chemotherapy in the era of intensity-modulated radiotherapy
por: Xie, Ruifei, et al.
Publicado: (2016)

Outcomes of Adding Induction Chemotherapy to Concurrent Chemotherapy for Nasopharyngeal Carcinoma Patients with Moderate-Risk in the Intensity-Modulated Radiotherapy Era
por: Su, Zhen, et al.
Publicado: (2020)

Nomogram Predicting the Benefits of Adding Concurrent Chemotherapy to Intensity-Modulated Radiotherapy After Induction Chemotherapy in Stages II–IVb Nasopharyngeal Carcinoma
por: Liu, Sai-Lan, et al.
Publicado: (2020)

Long-term outcomes of nasopharyngeal carcinoma patients with T1-2 stage in intensity-modulated radiotherapy era
por: Niu, Xiaoshuang, et al.
Publicado: (2022)

Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy and intensity-modulated radiotherapy alone for stage II nasopharyngeal carcinoma
por: Chen, Kai-Hua, et al.
Publicado: (2016)

Role of Chemotherapy in Stage II Nasopharyngeal Carcinoma Treated with Curative Radiotherapy
por: Kang, Min Kyu, et al.
Publicado: (2015)

Comparison of the efficacy between intensity-modulated radiotherapy and two-dimensional conventional radiotherapy in stage II nasopharyngeal carcinoma
por: Pan, Xin-Bin, et al.
Publicado: (2017)

Nedaplatin-based chemotherapy or cisplatin-based chemotherapy combined with intensity-modulated radiotherapy achieve similar efficacy for stage II-IVa nasopharyngeal carcinoma patients
por: Deng, Chao, et al.
Publicado: (2022)

The impairment of induction chemotherapy for stage II nasopharyngeal carcinoma treated with intensity‐modulated radiotherapy with or without concurrent chemotherapy: A propensity score‐matched analysis
por: Lai, YuLin, et al.
Publicado: (2022)

Individualized Concurrent Chemotherapy for Patients with Stage III–IVa Nasopharyngeal Carcinoma Receiving Neoadjuvant Chemotherapy Combined with Definitive Intensity-Modulated Radiotherapy
por: Ji, Pengjie, et al.
Publicado: (2023)

ERRATUM: Role of Chemotherapy in Stage II Nasopharyngeal Carcinoma Treated with Curative Radiotherapy
por: Kang, Min Kyu, et al.
Publicado: (2016)

Apolipoprotein A-I Is a Prognosticator of Nasopharyngeal Carcinoma in the Era of Intensity-modulated Radiotherapy
por: Chang, Hui, et al.
Publicado: (2018)

Prognostic Value of Inflammatory Markers in Nasopharyngeal Carcinoma Patients in the Intensity-Modulated Radiotherapy Era
por: Li, Qian, et al.
Publicado: (2021)

Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era
por: Zhang, Lu-Ning, et al.
Publicado: (2015)

Development and prospective validation of a risk score model in guiding individualized concurrent chemoradiotherapy in stage II nasopharyngeal carcinoma in intensity‐modulated radiotherapy era
por: Yang, Shan‐Shan, et al.
Publicado: (2021)

Prognostic score models for survival of nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy and chemotherapy
por: Zeng, Lei, et al.
Publicado: (2015)

Intensity-modulated radiotherapy with simultaneous modulated accelerated boost technique and chemotherapy in patients with nasopharyngeal carcinoma
por: Fareed, Muhammad M, et al.
Publicado: (2013)

Should All Nasopharyngeal Carcinoma with Paranasal Sinus Invasion Be Staged as T3 in the Intensity-Modulated Radiotherapy Era? A Study of 1811 Cases
por: Zhang, Yuan, et al.
Publicado: (2016)

Ten-Year Outcomes Of Intensity-Modulated Radiotherapy (IMRT) Combine With Chemotherapy Versus IMRT Alone For Stage II Nasopharyngeal Carcinoma In The Real-World Study (RWD)
por: Ding, Xing-Chen, et al.
Publicado: (2019)

The impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with advanced-stage nasopharyngeal carcinoma in an era of intensity-modulated radiotherapy
por: Guo, Shan-Shan, et al.
Publicado: (2015)

Concurrent chemoradiotherapy versus radiotherapy alone for locoregionally advanced nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: a meta-analysis
por: He, Yan, et al.
Publicado: (2018)

Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma
por: Aftab, Omer, et al.
Publicado: (2020)

Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy
por: Zhang, Lu, et al.
Publicado: (2015)

Adding Concurrent Chemotherapy to Intensity-Modulated Radiotherapy Does Not Improve Treatment Outcomes for Stage II Nasopharyngeal Carcinoma: A Phase 2 Multicenter Clinical Trial
por: Huang, Xiaodong, et al.
Publicado: (2020)

Intensity-modulated radiotherapy provides better quality of life than two-dimensional conventional radiotherapy for patients with stage II nasopharyngeal carcinoma
por: Pan, Xin-Bin, et al.
Publicado: (2017)

Clinical Outcome and Prognostic Factors of Intensity-Modulated Radiotherapy for T4 Stage Nasopharyngeal Carcinoma
por: Luo, Yangkun, et al.
Publicado: (2016)

Analysis of intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma
por: Wu, Shihai, et al.
Publicado: (2020)

Prognostic value of hepatitis B viral infection in patients with nasopharyngeal carcinoma in the intensity-modulated radiotherapy era
por: Zheng, Shuo-Han, et al.
Publicado: (2021)

Comparing treatment outcomes of different chemotherapy sequences during intensity modulated radiotherapy for advanced N-stage nasopharyngeal carcinoma patients
por: Sun, Xueming, et al.
Publicado: (2013)

Induction chemotherapy followed by intensity-modulated radiotherapy with reduced gross tumor volume delineation for stage T3–4 nasopharyngeal carcinoma
por: Xue, Fen, et al.
Publicado: (2017)

Intensity-modulated radiotherapy combined with sequential cisplatin and fluorouracil chemotherapy for locoregionally advanced nasopharyngeal carcinoma
por: Wu, Mingyao, et al.
Publicado: (2018)

Concurrent image-guided intensity modulated radiotherapy and chemotherapy following neoadjuvant chemotherapy for locally advanced nasopharyngeal carcinoma
por: Shueng, Pei-Wei, et al.
Publicado: (2011)

Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era: A Large-Scale Cohort Study
por: Chen, Qiu-Yan, et al.
Publicado: (2018)

Chemotherapy use and survival in stage II nasopharyngeal carcinoma
por: Pan, Xin-Bin, et al.
Publicado: (2017)

Multivariate NTCP Model of Hypothyroidism After Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma
por: Shen, Guanzhu, et al.
Publicado: (2021)

Gemcitabine/cisplatin induction chemotherapy before concurrent chemotherapy and intensity-modulated radiotherapy improves outcomes for locoregionally advanced nasopharyngeal carcinoma
por: Fangzheng, Wang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_t2ktbk52ah1t5oischre3t9m7f